Analyst Reco. Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
37.88 ^USD	+1.94%		+0.74%	+95.46%

Jun. 03	Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program	MT
Jun. 03	Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	Apr. 29	MT
William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT
Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating	23-05-09	MT
North American Morning Briefing : Stock Futures Dip as Higher Rate Fears Persist	23-03-09	DJ
Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy	23-01-03	MT
Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21	22-11-15	MT
Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	22-11-15	MT
BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3	22-09-12	MT
HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating	22-09-12	MT
Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating	22-08-10	MT
Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target	22-07-06	MT
Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating	22-05-31	MT
Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating	22-05-10	MT
Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating	22-03-02	MT
NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target	21-08-06	MT
NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target	21-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer